Dr Paul Mainwaring
Paul has worked as a medical oncologist for over 25 years, with an emphasis on basic, clinical, and translational research applying new technologies to deliver the best available personalised care to patients and their carers. He published extensively in the world’s leading cancer journals including the New England of Medicine, Lancet, Lancet Oncology, Journal of Clinical Oncology amongst others.
After Paul’s initial Medical Oncology training in Sydney at Royal Prince Alfred and Royal North Shore hospitals he moved to the Royal Marsden in London – Europe’s largest cancer hospital. Paul completed his MD in cell death at the Institute of Cancer Research and was appointed as a consultant at Guy’s, King’s, and St Thomas’ NHS Trusts in 1999.
In 2002, Paul returned to Australia as Director of Medical Oncology, Mater Adult Hospital and in 2008 Paul transferred across into private practice in Queensland continuing his translational & clinical research. As part of this work, he came across the disruptive nanotechnologies being developed in Queensland that could transform patient care.
In 2019, Paul transitioned across from working as a medical oncologist to XING Technologies and works alongside the brilliant team of researchers as Co-Founder, Executive Chairman & CEO. XING Technologies is a biotechnology company specialising in ground-breaking, disruptive nanotechnology to enable rapid, point-of-care diagnosis, screening and ongoing monitoring of cancer without requiring access to laboratory facilities and highly trained personnel.
MBBS, Medicine, University of Sydney, Australia.
MD, Institute of Cancer Research, University of London, England.